Categories AlphaGraphs, Earnings, Health Care
Infographic: Highlights of Moderna’s (MRNA) Q4 2023 earnings results
Biotechnology company Moderna, Inc. (NASDAQ: MRNA) reported a sharp decline in revenues and earnings for the fourth quarter of 2023.
Net income fell to $217 million or $0.55 per share in the December quarter from $1.47 billion or $3.61 per share in the same period of fiscal 2022.
The bottom line was negatively impacted by a 45% fall in revenues to $2.81 billion. There was a 43% drop in product revenues. The management reaffirmed its full-year 2024 product sales guidance at approximately $4 billion.
“We look forward to the anticipated approvals of our RSV vaccine beginning in the first half of the year. With multiple upcoming Phase 3 data readouts in 2024, we remain focused on commercial execution and continued investment in our pipeline with financial discipline,” said Moderna’s CEO Stéphane Bancel.
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
CCL Earnings: Highlights of Carnival Corporation’s Q4 2025 results
Cruise operator Carnival Corporation & plc (NYSE: CCL) on Friday reported an increase in revenue and adjusted earnings for the fourth quarter of fiscal 2025. Earnings topped analysts' expectations. Revenues
Lamb Weston (LW) Q2 2026 Earnings: Key financials and quarterly highlights
Lamb Weston Holdings, Inc. (NYSE: LW) reported its second quarter 2026 earnings results today. Net sales inched up 1% year-over-year to $1.62 billion. Net sales at constant currency remained flat.
Paychex reports higher Q2 FY26 revenue and earnings; EPS beats estimates
Paychex Inc. (NASDAQ: PAYX) on Friday reported stronger-than-expected adjusted earnings for the second quarter of fiscal 2026. Revenues grew 18% year-over-year. The Rochester-based human capital management solutions provider reported revenues
